BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

Bruton’s tyrosine kinase (BTK) is an essential component of multiple signaling pathways that regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising therapeutic target for various B cell malignancies and inflammatory diseases. Five small molecule inhibitors hav...

Descripción completa

Detalles Bibliográficos
Autores principales: Alu, Aqu, Lei, Hong, Han, Xuejiao, Wei, Yuquan, Wei, Xiawei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526392/
https://www.ncbi.nlm.nih.gov/pubmed/36183125
http://dx.doi.org/10.1186/s13045-022-01353-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526392/
https://www.ncbi.nlm.nih.gov/pubmed/36183125
http://dx.doi.org/10.1186/s13045-022-01353-w

Ejemplares similares